Previous 10 | Next 10 |
– Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment - – When provided similar efficacy and safety profiles for oral and injectable on-demand treatments for HAE attacks, adults and adolescents exp...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit taking pla...
2023-07-07 11:08:15 ET Next week marks the start of a crucial period as earnings season kicks off, with major companies from the financial, consumer, and technology sectors all set to release their quarterly financial results. Among the list of firms scheduled to announce their financia...
2023-07-07 10:07:00 ET Gainers: Castle Biosciences ( CSTL ) +43% . CareDx ( CDNA ) +20% . COMPASS Pathways ( CMPS ) +9% . TG Therapeutics ( TGTX ) +9% . KalVista Pharmaceuticals ( KALV ) +8% . Losers: PainReform ( P...
2023-07-07 06:32:55 ET KalVista Pharmaceuticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.77. Cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023, compared to $166.2 million on April 30, 2022. The decrease in the net cash positio...
2023-07-07 06:32:55 ET KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.77. Cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023, compared to $166.2 million on April 30, 2022. The decrease in the net cash position...
– Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis – – Real-world patient data show significant burden from HAE still remains on patients receiving modern long-t...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 European Academy of Allergy and Clinica...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 20...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medic...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...